| CRF patients (n = 79) | HMV patients (n = 83) | healthy patients (n = 29) | p-value |
---|---|---|---|---|
Demographic data | ||||
 Age (years) | 53 (41–62) | 55 (42–69) | 53 (41–64) | p = 0.537 |
Sex | ||||
 Female | 20 (25.3%) | 22 (26.5%) | 7 (24.1%) | p = 0.965 |
 Male | 59 (74.7%) | 61 (73.5%) | 22 (75.8%) |  |
Diagnosis/HMV indication | ||||
 COPD | 8 (10.1%) | 13 (15.7%) |  | p = 1.000 |
 RCDW | 5 (6.3%) | 4 (4.8%) |  |  |
 OHS | 26 (32.9%) | 26 (31.3%) |  |  |
 NMD | 19 (24.1%) | 20 (24.1%) |  |  |
 ALS | 14 (17.7%) | 12 (14.5%) |  |  |
 PD | 2 (2.5%) | 3 (3.6%) |  |  |
 SCT | 5 (6.3%) | 5 (6.0%) |  |  |
Interface | ||||
 Noninvasive |  | 68 (81.9%) |  |  |
 Invasive |  | 15 (18.1%) |  |  |
 HMV duration (months) |  | 6 (4–27) |  |  |
 O2 supplementation need |  |  |  |  |
 No | 45 (57.0%) | 47 (56.6%) |  | p = 1.000 |
 Yes | 34 (43.0%) | 36 (43.4%) |  |  |
Laboratory parameters | ||||
 RDW (%) | 14.5 (13.2–15.6) | 13.9 (13.2–15.3) | 12.8 (12.3–13.6) | p < 0.001 |
 HGB (g/L) | 130 (107–149) | 137 (121–148) | 141 (133–151) | p = 0.051 |
 HCT (L/L) | 0.39 (0.34–0.46) | 0.4 (0.37–0.45) | 0.41 (0.39–0.44) | p = 0.503 |
 RBC (Tera/L) | 4.42 (3.82–5.17) | 4.67 (4.18–5.02) | 4.7 (4.41–4.96) | p = 0.555 |
 MCV (fL) | 87.2 (85–89.5) | 87.8 (85.5–90.8) | 87.9 (85.6–89.8) | p = 0.653 |
 MCH (pg) | 29 (27.4–29.8) | 29.2 (28.4–30.5) | 29.6 (28.9–30.7) | p = 0.011 |
 MCHC (g/L) | 327 (315–337) | 333 (325–341) | 342 (334–347) | p < 0.001 |
 WBC (Giga/L) | 8.33 (6.77–10.86) | 8.71 (7.12–10.77) | 6.33 (5.7–7.65) | p < 0.001 |
 PLT (Giga/L) | 261 (215–346) | 248 (218–306) | 255 (231–282) | p = 0.317 |
 MPV (fL) | 10.35 (9.1–11.1) | 10.8 (9.9–11.5) | 10.3 (10–10.8) | p = 0.009 |
 CRP (mg/L) | 7.2 (2.5–19.1) | 6.35 (2.7–11.8) | 2.7 (1.6–10.6) | p = 0.065 |